Lakewood-Amedex Biotherapeutics Announce Participation at H.C. Wainwright Conference

Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright Conference

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT), recognized as a clinical-stage biotechnology venture, is set to present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference. This event will take place from September 14 to 16, 2026, in New York City.

Dr. Kelvin Cooper, the CEO of the company, will be leading a virtual presentation that will not only highlight the innovative pipeline of Lakewood-Amedex but also delve into their strategic vision for clinical development and business growth.

The focus of Lakewood-Amedex is their groundbreaking class of antimicrobials known as Bisphosphocin®, designed to combat infectious diseases effectively. This approach aims to tackle the growing issue of antibiotic resistance, which poses significant health risks globally, especially with strains like MRSA and VRE on the rise.

Conference Highlights

During the H.C. Wainwright conference, Dr. Cooper will engage in one-on-one discussions with vetted investors and prospective partners. It is an essential opportunity for Lakewood-Amedex to showcase its recent successes, clinical milestones, and future objectives—aligning with the industry's trends toward innovative healthcare solutions.

About Lakewood-Amedex

Lakewood-Amedex Biotherapeutics Inc. is committed to advancing new therapeutic solutions through rigorous research and development. Their Bisphosphocin® class exemplifies a strategic response to the biological challenges posed by resistant bacteria, making it a prominent contender in the biotech landscape for addressing infectious diseases. This class of antimicrobials not only shows fast-acting results but was also developed with a broad-spectrum mechanism to reduce the risks associated with antibiotic-resistant infections.

As an emerging entity in the biotechnology sector, Lakewood-Amedex continues to pave the way for innovative treatment protocols that respond to critical health challenges. By presenting at prestigious platforms such as the H.C. Wainwright Conference, they reinforce their commitment to transparency and communication with stakeholders and the public regarding their developmental progress and future initiatives.

Conclusion

As healthcare systems across the globe face unprecedented challenges from infectious diseases and the looming threat of antibiotic resistance, Lakewood-Amedex's advancements in antimicrobial therapy present a beacon of hope for future medical solutions. Mark your calendars for the H.C. Wainwright conference where insights from this promising company will be shared.

For more information about the company and its innovative products, visit Lakewood-Amedex.